Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy
Completed
- Conditions
- Prostate Cancer
- Interventions
- Device: myocardial PET imaging
- Registration Number
- NCT03535987
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Brief Summary
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 18
Inclusion Criteria
- Either clinically localized prostate cancer or biochemically-recurrent prostate cancer patients who are planned for at least 6 months ADT with a GnRH agonist and curative-intent radiation therapy per their oncologic providers.
- Over 50 years of age. Calculated 10-year Framingham General Cardiovascular Risk Score of ≥10% at the time of planned initiation of ADT.
- Patients must be able to read and understand English.
- Participants must sign the informed consent form.
Exclusion Criteria
- Prior treatment with GnRH agonist therapy.
- History of active asthma or other reactive airway disease.
- Ischemic cardiac event (myocardial infarction, unstable angina) within the preceding 6 months.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Observational myocardial PET imaging To determine the feasibility of using myocardial PET imaging
- Primary Outcome Measures
Name Time Method number of subjects who successfully complete Rb-82 myocardial PET Imaging assessments 12-18 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States